The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5

摘要

BackgroundWhile the dose of allopurinol is limited in patients with chronic kidney disease (CKD), information is lacking concerning the efficacy, safety, and maintenance dose of febuxostat in Chinese patients with hyperuricemia and with CKD stages 3-5.MethodsA single center, prospective cohort study was conducted in patients with CKD stages 3-5 and with hyperuricemia who had not yet begun to undergo renal replacement therapy. We enrolled 208 patients who were newly treated with febuxostat (n=112) or allopurinol (n=96) in this study. The efficacy of febuxostat was determined by the proportion of patients with serum uric acid (sUA)360 mu mol/L at the end of the study and changes of renal function.ResultsThe target of sUA360 mu mol/L was reached by 96.4% of participants in the febuxostat group and 37.5% in the allopurinol group at 6 months. The eGFR in the febuxostat group showed an increase from 28.45 to 30.65mL/min/1.73m(2) at 6 months, while in the allopurinol group, the eGFR decreased from 28.06 to 24.39mL/min/1.73m(2). Linear regression analysis showed that the reduction in sUA was significantly associated with an increase in eGFR and decrease in proteinuria. We found that 83.0% of the patients could remain with sUA360 mu mol/L at a maintenance dose of febuxostat 20mg/day.ConclusionFebuxostat had superior urate-lowering efficacy to that of allopurinol in Chinese Han patients with hyperuricemia with CKD stages 3-5, and the reduction in sUA levels was associated with a slower progression of renal function.